These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35337673)

  • 21. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities.
    Khetsuriani N; Perehinets I; Nitzan D; Popovic D; Moran T; Allahverdiyeva V; Huseynov S; Gavrilin E; Slobodianyk L; Izhyk O; Sukhodolska A; Hegazi S; Bulavinova K; Platov S; O'Connor P
    Vaccine; 2017 Aug; 35(36):4769-4776. PubMed ID: 28528761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
    Morales M; Nnadi CD; Tangermann RH; Wassilak SG
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.
    Burns CC; Shaw J; Jorba J; Bukbuk D; Adu F; Gumede N; Pate MA; Abanida EA; Gasasira A; Iber J; Chen Q; Vincent A; Chenoweth P; Henderson E; Wannemuehler K; Naeem A; Umami RN; Nishimura Y; Shimizu H; Baba M; Adeniji A; Williams AJ; Kilpatrick DR; Oberste MS; Wassilak SG; Tomori O; Pallansch MA; Kew O
    J Virol; 2013 May; 87(9):4907-22. PubMed ID: 23408630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.
    Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG
    Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017.
    Diop OM; Asghar H; Gavrilin E; Moeletsi NG; Benito GR; Paladin F; Pattamadilok S; Zhang Y; Goel A; Quddus A
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(20):538-542. PubMed ID: 28542124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outbreaks of Circulating Vaccine-Derived Poliovirus in the World Health Organization Western Pacific Region, 2000-2021.
    Kitamura K; Shimizu H
    Jpn J Infect Dis; 2022 Sep; 75(5):431-444. PubMed ID: 36047174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Threat of resurgence or hope for global eradication of poliovirus?
    Kim CY; Piamonte B; Allen R; Thakur KT
    Curr Opin Neurol; 2023 Jun; 36(3):229-237. PubMed ID: 37078665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A circulating vaccine-derived poliovirus type 2 outbreak in a chronic conflict setting: a descriptive epidemiological study in South Sudan - 2020 to 2021.
    Tegegne AA; Anyuon AN; Legge GA; Ferede MA; Isaac Z; Laku KA; Biadgilign S; Kilo OTD; Ndenzako F; Modjirom N; Olu OO; Maleghemi S
    BMC Infect Dis; 2023 Nov; 23(1):816. PubMed ID: 37990165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Kalkowska DA; Voorman A; Pallansch MA; Wassilak SGF; Cochi SL; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1():A12-A18. PubMed ID: 33962838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options.
    Kalkowska DA; Pallansch MA; Cochi SL; Thompson KM
    J Infect Dis; 2021 Nov; 224(9):1529-1538. PubMed ID: 33885734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
    Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA
    BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
    Harutyunyan V; Quddus A; Pallansch M; Zipursky S; Woods D; Ottosen A; Vertefeuille J; Lewis I
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A70-A78. PubMed ID: 35282924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress Toward Polio Eradication - Worldwide, January 2019-June 2021.
    Bigouette JP; Wilkinson AL; Tallis G; Burns CC; Wassilak SGF; Vertefeuille JF
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1129-1135. PubMed ID: 34437527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
    Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S
    J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.
    Etsano A; Damisa E; Shuaib F; Nganda GW; Enemaku O; Usman S; Adeniji A; Jorba J; Iber J; Ohuabunwo C; Nnadi C; Wiesen E
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):770-3. PubMed ID: 27490081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M
    Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.